New drug combo aims to shrink tumors before cervical cancer surgery
NCT ID NCT07205497
Summary
This study is testing whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery works better for treating locally advanced cervical cancer. About 54 participants will receive the drug combination for three cycles, followed by surgery. Researchers will check if this approach helps eliminate more cancer cells before surgery and monitor the safety of the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sun Yat-sen Memorial Hospital of the Sun Yat-sen University
Guangzhou, Guangdong, 537216, China
Conditions
Explore the condition pages connected to this study.